Mogamulizumab Efficacy is Underscored by its Associated Rash that Mimics Cutaneous T-cell Lymphoma: A Retrospective Single-Centre Case Series

CONCLUSIONS: MAR has the potential to create a significant management problem for patients on mogamulizumab. Misidentification of MAR as recurrent CTCL may detrimentally result in the premature discontinuation of mogamulizumab in patients whose disease is historically hard to treat. Thorough clinicopathologic investigation of new lesions during treatment with mogamulizumab is required to inform ideal treatment decisions and achieve better outcomes.PMID:34427917 | DOI:10.1111/bjd.20708

Source: The British Journal of Dermatology - August 24, 2021 Category: Dermatology Authors: N A Trum J Zain X U Martinez V Parekh M Afkhami F Abdulla K R Carson S T Rosen C L Bennett C Querfeld Source Type: research